Ibrance and Sebaceous hyperplasia - a phase IV clinical study of FDA data

Summary:

We study 104,648 people who take Ibrance (palbociclib) or have Sebaceous hyperplasia. No report of Sebaceous hyperplasia is found in people who take Ibrance.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.

What is Sebaceous Hyperplasia?

Sebaceous hyperplasia (a disorder of the sebaceous glands in which they become enlarged) is found to be associated with 16 drugs and 70 conditions by eHealthMe. Check the latest studies of Sebaceous hyperplasia.

On Oct, 28, 2025

No report is found.

Do you take Ibrance and have Sebaceous hyperplasia?

- Check whether Sebaceous hyperplasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Ibrance (104,433 reports)

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sebaceous hyperplasia:

Sebaceous hyperplasia

Browse all the conditions that are associated with Sebaceous hyperplasia:

Sebaceous hyperplasia

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.